Tag: PXL065
Poxel Presents Phase II (DESTINY-1) Results of PXL065 for the Treatment of NASH at AASLD The Liver Meeting® 2022 – 11/07/2022 8:15 PM
– “Late-breaking abstract” selected by the AASLD as one of the best of the 2022 edition (“Best of the Liver Meeting”) – The phase II study of PXL065 for the…
Poxel Obtains Orphan Drug Designation (ODD) from the FDA for PXL065 and PXL770
By Hector Chaunu Published on 05/17/2022 at 6:02 p.m. Photo credit © Reuters …